TCT

This channel contains news about the annual Transcatheter Cardiovascular Therapeutics (TCT) conference presented by the Cardiovascular Research Foundation (CRF). It includes coverage from the annual meeting and links CRF news. TCT is the premier conference for the subspecialty of interventional cardiology, including the new subspecialty areas of transcatheter structural heart procedures. 

Sapien 3 valve for VIV (valve in valve) procedures cleared by FDA
Feature | Heart Valve Technology | June 06, 2017 | Dave Fornell

June 6, 2017 — The U.S. Food and Drug Administration (FDA) has granted market clearance for aortic and mitral valve-...

LivaNova Announces Positive Data for Perceval Sutureless Valve at AATS 2017
News | Heart Valve Technology | May 31, 2017

May 31, 2017 — LivaNova PLC recently announced the presentation of data from multiple studies demonstrating the...

The Boston Scientific Lotus TAVR Valve
Feature | Heart Valve Technology | May 25, 2017

May 25, 2017 — Positive results from the...

Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve
News | Heart Valve Technology | May 24, 2017

May 24, 2017 — Late-breaking data presented at EuroPCR 2017 demonstrating excellent clinical outcomes for...

Shockwave Medical Announces CE Mark for Coronary Lithoplasty System and Activities at EuroPCR 2017
News | Cath Lab | May 23, 2017

May 23, 2017 — Shockwave Medical announced last week CE mark for the company’s Coronary Lithoplasty System for the...

FDA Clears Teleflex Arrow AC3 Optimus Intra-Aortic Balloon Pump (IABP)
Technology | Intra-Aortic Balloon Pumps (IABP) | May 02, 2017

May 2, 2017 — The U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the Teleflex Inc. AC3 Optimus...

a list of SCAI late breaking trial presentations
Feature | SCAI | May 01, 2017

May 30, 2017 — The Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions took...

the Impella pVAD improves survival, mortality in AMI heart attack with cardiogenic shock

Early use of the Impella percutaneous ventricular assist device prior to angioplasty may significantly improve survival for patients in cardiogenic shock.

Feature | Hemodynamic Support Devices | April 28, 2017 | Dave Fornell

Recent clinical study data presented at the American College of Cardiology (ACC) 2017 meeting show new treatment...

Tryton Medical, Side Branch Stent, first U.S. commercial case, New York-Presbyterian Hospital, Columbia University Medical Center
News | Stents Bifurcation | March 31, 2017

March 31, 2017 — Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side...

Videos | Stents Bioresorbable | March 30, 2017

Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses...

microbleeds, brain bleeds caused by TAVR

An MRI brain scan showing multiple microbleeds in a transcatheter aortic valve replacement (TAVR) patient from the study.

Feature | Heart Valve Technology | March 23, 2017

March 22, 2017 — A quarter of the patients in a single-center study of 84 patients undergoing transcatheter aortic...

Medtronic Corevalve Evolut Pro, TAVR system
Feature | Heart Valve Technology | March 22, 2017

March 22, 2017 – The U.S. Food and Drug Administration (FDA) and granted market clearance to the Medtronic CoreValve...

RESOLVE study, RESOLVE trial, subclinical leaflet thrombosis

A CT study from the RESOLVE Trial showing valve leaflet thrombosis on a TAVR device. The trial examined a range of surgical and transcatheter valves to show thrombosis is found across both types of devices. It also examined if anticoagulation or antiplatelet therapy could reduce thrombosis and allow a greater range of leaflet motion.

Feature | Heart Valve Technology | March 21, 2017

March 21, 2017 — About 12 percent of patients undergoing aortic valve replacement developed non-symptomatic blood...

BVS, Absorb stent, bioresorbable scaffold, ABSORB III data, ABSORB III results
Feature | Stents Bioresorbable | March 21, 2017 | Dave Fornell

March 21, 2017 — In the late-breaking ABSORB III Trial two year results presented at the American College of...

iFR, iFR vs. FFR, ACC late breaking trial, iFR-SWEDEHEART, DEFINE-FLAIR, Justin E. Davies,

Matthias Götberg, principal investigator for the iFR-SWEDEHEART study, and Justin E. Davies, lead investigator for the DEFINE-FLAIR trial, share key points of their study with DAIC editor Dave Fornell at ACC.17. The trials showed iFR is equal in outcomes to FFR in assessing coronary lesions. 

Feature | FFR Technologies | March 20, 2017

March 20, 2017 — For patients experiencing angina (chest pain) or a heart attack, instantaneous wave-free ratio (iFR...

Overlay Init